BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17680034)

  • 1. Antitumour bis(cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives.
    Abeysinghe PM; Harding MM
    Dalton Trans; 2007 Aug; (32):3474-82. PubMed ID: 17680034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organometallic anticancer agents: cellular uptake and cytotoxicity studies on thiol derivatives of the antitumor agent molybdocene dichloride.
    Waern JB; Dillon CT; Harding MM
    J Med Chem; 2005 Mar; 48(6):2093-9. PubMed ID: 15771451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
    Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
    Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding and hydrolysis studies of antitumoural titanocene dichloride and Titanocene Y with phosphate diesters.
    Erxleben A; Claffey J; Tacke M
    J Inorg Biochem; 2010 Apr; 104(4):390-6. PubMed ID: 20036426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, characterization, cytotoxicity, and hydrolytic behavior of C2- and C1-symmetrical Ti(IV) complexes of tetradentate diamine bis(phenolato) ligands: a new class of antitumor agents.
    Peri D; Meker S; Shavit M; Tshuva EY
    Chemistry; 2009; 15(10):2403-15. PubMed ID: 19156656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordination chemistry of the antitumor metallocene molybdocene dichloride with biological ligands.
    Waern JB; Harding MM
    Inorg Chem; 2004 Jan; 43(1):206-13. PubMed ID: 14704069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inclusion complexes of the antitumour metallocenes Cp(2)MCl(2) (M = Mo, Ti) with cucurbit[n]urils.
    Buck DP; Abeysinghe PM; Cullinane C; Day AI; Collins JG; Harding MM
    Dalton Trans; 2008 May; (17):2328-34. PubMed ID: 18414758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumour metallocenes: structure-activity studies and interactions with biomolecules.
    Harding MM; Mokdsi G
    Curr Med Chem; 2000 Dec; 7(12):1289-303. PubMed ID: 11032972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudo-halide derivatives of titanocene: synthesis and cytotoxicity studies.
    Claffey J; Deally A; Gleeson B; Hogan M; Méndez LM; Müller-Bunz H; Patil S; Wallis D; Tacke M
    Metallomics; 2009 Nov; 1(6):511-7. PubMed ID: 21305159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic studies of substituted titanocene and ansa-titanocene anticancer drugs.
    Gómez-Ruiz S; Kaluderović GN; Prashar S; Polo-Cerón D; Fajardo M; Zizak Z; Sabo TJ; Juranić ZD
    J Inorg Biochem; 2008 Aug; 102(8):1558-70. PubMed ID: 18353439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the cytotoxicity and particle action in human cancer cells of titanocene-functionalized materials with potential application against tumors.
    García-Peñas A; Gómez-Ruiz S; Pérez-Quintanilla D; Paschke R; Sierra I; Prashar S; del Hierro I; Kaluđerović GN
    J Inorg Biochem; 2012 Jan; 106(1):100-10. PubMed ID: 22112846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the cytotoxicity of titanocene dichloride by aging in organic co-solvent.
    Ravera M; Cassino C; Monti E; Gariboldi M; Osella D
    J Inorg Biochem; 2005 Dec; 99(12):2264-9. PubMed ID: 16209887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heteroaryl substituted titanocenes as potential anti-cancer drugs.
    Sweeney N; Gallagher WM; Müller-Bunz H; Pampillón C; Strohfeldt K; Tacke M
    J Inorg Biochem; 2006 Sep; 100(9):1479-86. PubMed ID: 16764931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bis(cyclopentadienyl)titanium complexes of naphthalene-1,8-dithiolates, biphenyl 2,2'-dithiolates, and related ligands.
    Aucott SM; Kilian P; Milton HL; Robertson SD; Slawin AM; Woollins JD
    Inorg Chem; 2005 Apr; 44(8):2710-8. PubMed ID: 15819557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new generation of anticancer drugs: mesoporous materials modified with titanocene complexes.
    Pérez-Quintanilla D; Gómez-Ruiz S; Zizak Z; Sierra I; Prashar S; del Hierro I; Fajardo M; Juranić ZD; Kaluderović GN
    Chemistry; 2009; 15(22):5588-97. PubMed ID: 19370742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of anticancer titanocene derivatives: an insight from quantum chemical calculations.
    Sponer JE; Leszczynski J; Sponer J
    J Phys Chem B; 2006 Oct; 110(39):19632-6. PubMed ID: 17004831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative activity of Titanocene Y against tumor colony-forming units.
    Oberschmidt O; Hanauske AR; Pampillón C; Sweeney NJ; Strohfeldt K; Tacke M
    Anticancer Drugs; 2007 Mar; 18(3):317-21. PubMed ID: 17264765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of cytotoxicity of titanocene-functionalized mesoporous materials by the increase of the titanium content.
    Kaluderović GN; Pérez-Quintanilla D; Zizak Z; Juranić ZD; Gómez-Ruiz S
    Dalton Trans; 2010 Mar; 39(10):2597-608. PubMed ID: 20179853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioorganometallic fulvene-derived titanocene anti-cancer drugs.
    Strohfeldt K; Tacke M
    Chem Soc Rev; 2008 Jun; 37(6):1174-87. PubMed ID: 18497930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electronic structure of bent titanocene complexes with chelated dithiolate ligands.
    Cooney JJ; Cranswick MA; Gruhn NE; Joshi HK; Enemark JH
    Inorg Chem; 2004 Dec; 43(25):8110-8. PubMed ID: 15578851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.